<i id='7B645B473A'><strike id='7B645B473A'><tt id='7B645B473A'><pre id='7B645B473A'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem
read more
Rep.LarryBucshon(R-Ind.)receivedasignificantamountofcampaigndonationsfromthepharmaceuticalindustryin
read more
EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3
read more1:29Policelightsonastreetatnight.STOCKPHOTO/GettyImagesTwopoliceofficerswerecriticallyinjuredonFrida
